Small Cap Feast

Small Cap Feast – 07 January 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 919

Total number of AIM Companies trading: 844*
* As at 31 December 2018

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 89*

Total number of NEX Growth Market Companies trading: 87*
* As at 31 December 2018

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 139*

Total number of Standard List Companies trading: 130*
* As at 31 December 2018

Dish of the Day:

No Joiners today

Off the Menu:

No Leavers Today

Dish of the Day:

No Joiners today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Specialist Funds)

The Global Sustainability Trust -aiming for attractive risk-adjusted returns by investing primarily in private market investments that are expected to have a positive environmental and social impact raising c.£200m. Due 31 Jan 2019.


Greenfields Petroleum (TSX-V:GNF)  production focused company with operated assets in Azerbaijan seeking AIM dual listing including $60m private placement. Mkt cap $12.6m CAD. Expected late January 2019.

Breakfast Buffet

Integumen* (SKIN.L) 0.6p £2.7m

Positive results of major restructuring and accelerated growth in product sales and contract test services at Labskin.

(Unaudited) revenue for FY Dec 2018 is more than 200% of the 2017 level (of £238,000).

Order book at 31/12/2018 £247,000 (31/12/2017 – £37,000)

H2 – 480% increase in Labskin sales

H2 – STOER For Men skin products division reached break-even and recurring orders to June 2019 to maintain at or above breakeven

Disposal of TSPro GmbH has removed c€1.34m (£1.19m) of short and long-term obligations

New Product Development of CBD oils and STOER For Men

Labskin AI and the integration of data analytics using the Labskin-On-A-Chip portable microbiology laboratory testing with results expected in early Q2 2019

Labskin Cannabinoid (CBD) testing protocols prepared and will be offered to existing and new skin-care clients

Combined debt and equity funding of over £900,000 completed


Mattioli Woods (MTW.L) 660p £174m

HYNov18 trading update from the specialist wealth management and employee benefits business.

EBITDA margin in first half substantially ahead of 20% target

Total client assets at the period end of £8.8bn

Gross discretionary assets under management of £2.4bn

Recent acquisitions performing and integrating well

Strong financial position, with cash of over £16m

Profit outlook for year in line with management’s expectations


Physiomics* (PYC.L) 3.85p £2.77m

Physiomics will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 Jan 2019 during the JP Morgan Healthcare Conference week. During this week, many of the world’s most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners. Over three thousand attendees are expected to participate in over seven thousand organised 1-1 meetings.  Physiomics has confirmed meetings with oncology companies from around the world interested in finding out more about our Virtual Tumour platform and how it can enhance their drug discovery and development programs.


Medaphor (MED.L) 7.75p £12.14m

The “intelligent ultrasound software and simulation company, announces that Group turnover for the year to 31 Dec 2018, which was generated entirely by the Group’s Simulation Division, is expected to grow by approximately 27% to between £5.3m and £5.4m (2017: £4.2m). The pre-exceptionals EBITDA loss for the year is expected to be around £3m (2017: Loss, £1.7m). This includes approximately £1.5m of primarily R&D expenses attributable to investment in the Group’s Clinical Artificial Intelligence Division which was established with the acquisition of Intelligent Ultrasound Limited (“IUL”) on 6 Oct 2017 (3 months to 31 Dec 2017, IUL overheads: £0.2m).  Group management, PLC costs and share-based payment charges included in the adjusted loss are expected to be £0.9m (2017: £0.8m).”


Eagle Eye Solutions Group (EYE.L) 96.7p £24.6m

The SaaS technology company that allows businesses to create a real-time connection with their customers through digital promotion and loyalty services, announced a new five-year contract with Waitrose Limited. 

The employee owned British supermarket chain will be taking advantage of Eagle Eye’s AIR platform to improve their digital marketing proposition.

This contract signing extends Eagle Eye’s existing relationship with John Lewis Plc that was first announced in May 2017, enabling the platform to connect to all customers across the group.

The Company continues to trade in-line with the Board’s expectations.


Anglo African Oil and Gas (AAOG.L) 16.55p £29.45m

Schlumberger wireline logging completed on the TLP-103C well has confirmed multiple discoveries at its Tilapia licence in the Republic of the Congo. Wireline logging validates the initial results identified during drilling the targeted R1/R2/R3 and the Mengo reservoirs and confirms oil columns amounting to an aggregate of 44 metres across the identified horizons.

26 metre oil column in the Mengo identified in sandstones interbedded with claystones between 1874,8mMD and 1900,8mMD

An aggregate 13 metres of oil columns across the new horizons identified between the R3 and the Mengo horizons in three layers of sandstones between 1473mMD and 1685,5mMD

5 metre oil column identified in the R2 reservoir between 1282,7mMD and 1287,7mMD in line with the TLP-101V well located in fine sandstones

Modular formation dynamics tests showed that the R2 reservoir is not depleted, confirming an onshore hydrocarbon system underlying the Tilapia licence area.


Mpac Group (MPAC.L) 109p £21.99m

The “global leader in ‘Make, Pack, Test and Service’ high speed packaging solutions, provides a pre-close trading update for the year ended 31 Dec 2018.

We are pleased to report that sales growth continued in the second half of the year. We also launched a number of new product innovations at the Chicago Pack Expo trade show which were well received by customers and resulted in new contract wins. During the second half we also secured a number of contracts for delivery in 2019.

Considerable progress has been made in delivering on the Group’s strategic priorities and in resolving the two technically challenging legacy contracts. The UK legacy contract has been resolved and we have agreed the commercial approach to resolving the Canadian contract which is expected to be finalised during 2019.

Also announced that sales and profit before tax are expected to be in line with market expectations (subject to year end audit), supported by a strong closing orderbook which will provide a platform for continued growth in 2019.”

FYDec18E rev £57m and PBT £1.35m.


Nektan (NKTN.L) 14p £6.6m

The fast growing international gaming technology platform and services provider, announced another record quarter for the second three months of the financial year ending 30 June 2019”.

Total Gaming Revenue increased 28.4% to £8.6m in Q2 FY19, up from £6.7m in Q1 FY19 (up 83% on Q2 FY18).

In Q2 FY19 Nektan’s technology generated over £222.5m in Cash Wagers, up from £182.4m in Q1 FY19, representing an increase of £40.1m (22% growth).

Growth driven by a significant increase in the number of unique players on the B2B platform, helped by 4 new partners going live.

Premium gaming content added across both B2C and B2B divisions.

Additional partners signed up across both B2C and B2B divisions, including BetVictor in B2B.

Growth trajectory should result in European EBITDA break-even by the end of FY19 (30 June 2019).


RedEmperor (RMP.L) 3.5p £14.89m

The “natural resource exploration company, provided a further operational update with respect to preparations for the drilling of the Winx-1 exploration well, located on the Western Blocks, North Slope of Alaska.

Ice road construction for the Winx-1 exploration well has commenced

Winx-1 Permit to Drill submitted on schedule

Spud of the Winx-1 exploration well on schedule for mid-late February 2019”


4D pharma (DDDD.L) 107.75p £70.57m

The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings.

The alliance brings together MD Anderson’s translational medicine and clinical research capabilities with 4D’s expertise in the discovery and development of Live Biotherapeutics. The collaboration will initially assess 4D’s lead oncology candidate, MRx0518, as a potential treatment for solid tumours.

The first clinical study, an open label Phase I study of MRx0518 in combination with Keytruda® and conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA, has been initiated and is due to open shortly. The study will enrol up to 132 patients with metastatic cancer across multiple histologies (non-small cell lung cancer, renal cell carcinoma, bladder cancer and melanoma) who have failed prior anti-PD-1 therapy.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.